A Phase 3 interventional study of Ferric Carboxymaltose (FCM) in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.
Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 29th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 1st registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:
Biocruces Bizkaia Health Research Institute · Sites in Spain
Ages 18+
Children's Hospital of Orange County
Ages 1–18
Helsinki University Central Hospital
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 24 · Phase 4 23
First in 2005; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 156 across the 54 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
19 studies in Anemia by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 19 studies in Anemia by Daiichi Sankyo, this one is the 13th largest by enrollment, is one of 6 that started in 2005, is one of 15 in phase 3, and was the 7th registered.
Daiichi Sankyo’s Anemia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing ferric carboxymaltose in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 19 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the long term safety and tolerability of an iron maintenance dosing strategy utilizing VIT45 in the treatment of anemia of non-dialysis dependent chronic kidney disease (NDD-CKD). This study is a long term extension to protocol 1VIT04004 (NCT00317239).
The primary objective of this study is to evaluate the long term safety and tolerability of an iron maintenance dosing strategy utilizing VIT45 in the treatment of anemia of non-dialysis dependent chronic kidney disease (NDD-CKD). This study is a long term extension to protocol 1VIT04004.
In this study patients that complete protocol 1VIT 04004 or are discontinued will be offered to participate in this extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
Drug: Ferric Carboxymaltose (FCM)
maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
Incidence of Treatment-emergent Adverse Events
Time frame: 44 week study duration
Hospitals and medical clinics
| Milestone | Ferric Carboxymaltose (FCM) |
|---|---|
| Started | 127 |
| Completed | 104 |
| Not completed | 23 |
| each event | Ferric Carboxymaltose (FCM) |
|---|---|
| Incidence of Treatment-emergent Adverse Events | 84 |
Collected over 1 year and 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose (FCM) | — | 23/127 (18.1%) | 23/127 (18.1%) |
| Event | Ferric Carboxymaltose (FCM) |
|---|---|
| CellulitisInfections and infestations | 2/127 |
| Acute myocardial infarctionCardiac disorders | 1/127 |
| Angina unstableCardiac disorders | 1/127 |
| Coronary artery diseaseCardiac disorders | 1/127 |
| Abdominal painGastrointestinal disorders | 1/127 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 1/127 |
| Large intestine perforationGastrointestinal disorders | 1/127 |
| NauseaGastrointestinal disorders | 1/127 |
| Rectal hemorrhageGastrointestinal disorders | 1/127 |
| VomitingGastrointestinal disorders | 1/127 |
| Event | Ferric Carboxymaltose (FCM) |
|---|---|
| Odema peripheralGeneral disorders | 9/127 |
| Urinary tract infectionInfections and infestations | 7/127 |
| HypertensionVascular disorders | 7/127 |
| Age, Categorical(Participants) | Ferric Carboxymaltose (FCM) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 61 |
| >=65 years | 66 |
| Age, Continuous(years) | Ferric Carboxymaltose (FCM) |
|---|---|
| Mean | 65.6 ± 13.39 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose (FCM) |
|---|---|
| Female | 85 |
| Male | 42 |
| Region of Enrollment(participants) | Ferric Carboxymaltose (FCM) |
|---|---|
| United States | 127 |
The record gives a start of Jun 2005, a primary completion of Mar 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 8 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose